More recently, an experimental study suggests that the prokineticin (PK) 2/PK receptor (PKR) pathway plays a crucial role in the pathogenesis of diabetic cardiomyopathy and that metformin prevents diabetes-induced glucose and lipid metabolism dysfunction, cardiomyocyte apoptosis, fibrosis, and cardiac insufficiency by stimulating PK2/PKR and the downstream AKT/GSK3β pathway (Yang et al., 2020). The gene discussed is EIF2AK2; the disease is diabetes mellitus.